Opsens Inc.

TSX:OPS Stock Report

Market Cap: CA$335.8m

Opsens Valuation

Is OPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OPS (CA$2.9) is trading below our estimate of fair value (CA$4.64)

Significantly Below Fair Value: OPS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OPS?

Key metric: As OPS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OPS. This is calculated by dividing OPS's market cap by their current revenue.
What is OPS's PS Ratio?
PS Ratio6.9x
SalesCA$48.35m
Market CapCA$335.77m

Price to Sales Ratio vs Peers

How does OPS's PS Ratio compare to its peers?

The above table shows the PS ratio for OPS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.1x
HTL Hamilton Thorne
3.2x9.1%CA$346.3m
PRN Profound Medical
21x52.7%CA$267.8m
ASG Aurora Spine
1.5xn/aCA$33.3m
CNVI Conavi Medical
10.8xn/aCA$38.1m
OPS Opsens
6.9x18.5%CA$335.8m

Price-To-Sales vs Peers: OPS is good value based on its Price-To-Sales Ratio (6.9x) compared to the peer average (20x).

Price to Sales Ratio vs Industry

How does OPS's PS Ratio compare vs other companies in the CA Medical Equipment Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
HTL Hamilton Thorne
3.2x9.1%US$247.68m
NSCI Nanalysis Scientific
1xn/aUS$30.74m
ASG Aurora Spine
1.5xn/aUS$23.81m
EVMT Evome Medical Technologies
0.2xn/aUS$8.27m
OPS 6.9xIndustry Avg. 3.2xNo. of Companies8PS020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: OPS is expensive based on its Price-To-Sales Ratio (6.9x) compared to the North American Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is OPS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OPS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.9x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: OPS is expensive based on its Price-To-Sales Ratio (6.9x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OPS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Nov ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Oct ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Sep ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Aug ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Jul ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Jun ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
May ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Apr ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Mar ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Feb ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Jan ’25n/a
CA$3.26
0%
10.2%CA$3.75CA$2.90n/a5
Dec ’24CA$2.88
CA$3.26
+13.2%
10.2%CA$3.75CA$2.90n/a5
Nov ’24CA$2.85
CA$3.26
+14.4%
10.2%CA$3.75CA$2.90n/a5
Oct ’24CA$1.77
CA$3.45
+94.9%
5.4%CA$3.75CA$3.25n/a5
Sep ’24CA$1.95
CA$3.54
+81.6%
7.5%CA$4.00CA$3.25n/a6
Aug ’24CA$1.89
CA$3.54
+87.4%
7.5%CA$4.00CA$3.25n/a6
Jul ’24CA$1.63
CA$3.54
+117.3%
7.5%CA$4.00CA$3.25n/a6
Jun ’24CA$1.65
CA$3.54
+114.6%
7.5%CA$4.00CA$3.25n/a6
May ’24CA$1.52
CA$3.54
+133.0%
7.5%CA$4.00CA$3.25n/a6
Apr ’24CA$1.64
CA$3.63
+121.0%
8.7%CA$4.00CA$3.25n/a6
Mar ’24CA$1.81
CA$3.70
+104.4%
7.9%CA$4.00CA$3.25n/a5
Feb ’24CA$1.94
CA$3.70
+90.7%
7.9%CA$4.00CA$3.25n/a5
Jan ’24CA$1.88
CA$3.73
+98.4%
6.7%CA$4.00CA$3.40n/a5
Dec ’23CA$2.23
CA$4.03
+80.7%
13.2%CA$5.00CA$3.40CA$2.885
Nov ’23CA$2.50
CA$4.23
+69.2%
21.6%CA$6.00CA$3.40CA$2.855

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

NeuPath Health

CA$9.0m

Provides chronic pain management services in Canada.

NPTH

CA$0.17

7D

6.3%

1Y

9.7%

Medical Facilities

CA$369.6m

Through its subsidiaries, owns and operates specialty hospitals and ambulatory surgery center in the United States.

DR

CA$15.55

7D

3.2%

1Y

79.1%

Carebook Technologies

CA$6.2m

Engages in the development and commercialization of digital health platforms for assessments, reporting, and targeted solutions in Canada, the United States, Europe, Latin America, Asia, and internationally.

CRBK

CA$0.05

7D

-37.5%

1Y

-28.6%